Literature DB >> 22694825

Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer.

Paul H Levine1, Chia C Portera, Heather J Hoffman, Sherry X Yang, Mikiko Takikita, Quyen N Duong, Stephen M Hewitt, Sandra M Swain.   

Abstract

BACKGROUND: Inflammatory breast cancer (IBC) is an aggressive form of breast cancer that on presentation resembles locally advanced breast cancer (LABC). This study identified molecular features of IBC and LABC to investigate pathogenesis.
MATERIALS AND METHODS: This study involved 100 IBC cases identified in a national IBC registry and 107 non-IBC LABC cases from the National Cancer Institute's Cooperative Breast Cancer Tissue Resource (CBCTR). Vascular endothelial growth factor D (VEGF-D) and E-cadherin levels and lymphatic vessel density (LVD) measured by podoplanin staining were examined by immunohistochemistry on paraffin-embedded tumor specimens. Intralymphatic tumor emboli (ILTE) were assessed in IBC and non-IBC tumors. IBC cases diagnosed by clinicians but not meeting the case definitions of the American Joint Committee on Cancer (AJCC) or the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute (NCI)(designated atypical IBC) were compared with AJCC- and/or SEER-defined cases (designated classic IBC).
RESULTS: E-cadherin levels were significantly higher in classic IBC cases compared with non-IBC cases (P = .031), whereas compared with classic IBC, patients with non-IBC LABC had significantly higher LVD (P = .0017) and VEGF-D levels (P < .0001). ILTE was marginally greater in classic IBC than in non-IBC (P = .046). The profile of laboratory values in atypical IBC cases more closely resembled those fitting classic IBC than LABC.
CONCLUSION: E-cadherin levels, LVD, VEGF-D expression, and to a lesser extent, ILTE differed between classic IBC and non-IBC LABC. The similarity of laboratory results between atypical IBC and classic IBC vs. LABC suggests the need for broadening both the AJCC and SEER case definitions for this disease.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22694825      PMCID: PMC7448289          DOI: 10.1016/j.clbc.2012.04.005

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  36 in total

1.  Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer.

Authors:  Guenther Gruber; Michele Ciriolo; Hans Joerg Altermatt; Stefan Aebi; Gilles Berclaz; Richard H Greiner
Journal:  Int J Cancer       Date:  2004-03       Impact factor: 7.396

2.  The Cooperative Breast Cancer Tissue Resource: archival tissue for the investigation of tumor markers.

Authors:  A G Glass; H Donis-Keller; C Mies; J Russo; B Zehnbauer; S Taube; R Aamodt
Journal:  Clin Cancer Res       Date:  2001-07       Impact factor: 12.531

3.  Cell-junctional and cytoskeletal organization in mouse blastocysts lacking E-cadherin.

Authors:  M Ohsugi; L Larue; H Schwarz; R Kemler
Journal:  Dev Biol       Date:  1997-05-15       Impact factor: 3.582

4.  Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer.

Authors:  Nicole J McCarthy; Xiaowei Yang; Ilona R Linnoila; Maria J Merino; Stephen M Hewitt; Allyson L Parr; Soonmyung Paik; Seth M Steinberg; Dan P Hartmann; Nejib Mourali; Paul H Levine; Sandra M Swain
Journal:  Clin Cancer Res       Date:  2002-12       Impact factor: 12.531

5.  Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study.

Authors:  Ilse Van der Auwera; Gert G Van den Eynden; Cecile G Colpaert; Steven J Van Laere; Peter van Dam; Eric A Van Marck; Luc Y Dirix; Peter B Vermeulen
Journal:  Clin Cancer Res       Date:  2005-11-01       Impact factor: 12.531

6.  Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature.

Authors:  Ivan Bièche; Florence Lerebours; Sengül Tozlu; Marc Espie; Michel Marty; Rosette Lidereau
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

7.  Inflammatory cancer of the breast: analysis of 114 cases.

Authors:  F Bozzetti; R Saccozzi; M De Lena; B Salvadori
Journal:  J Surg Oncol       Date:  1981       Impact factor: 3.454

8.  E-cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells.

Authors:  S S Kantak; R H Kramer
Journal:  J Biol Chem       Date:  1998-07-03       Impact factor: 5.157

9.  Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities?

Authors:  William F Anderson; Kenneth C Chu; Shine Chang
Journal:  J Clin Oncol       Date:  2003-06-15       Impact factor: 44.544

10.  Expression of vascular endothelial growth factor (VEGF) family members in breast cancer.

Authors:  J Kurebayashi; T Otsuki; H Kunisue; Y Mikami; K Tanaka; S Yamamoto; H Sonoo
Journal:  Jpn J Cancer Res       Date:  1999-09
View more
  8 in total

1.  MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer.

Authors:  Lei Huo; Yan Wang; Yun Gong; Savitri Krishnamurthy; Jing Wang; Lixia Diao; Chang-Gong Liu; Xiuping Liu; Feng Lin; William F Symmans; Wei Wei; Xinna Zhang; Li Sun; Ricardo H Alvarez; Naoto T Ueno; Tamer M Fouad; Kenichi Harano; Bisrat G Debeb; Yun Wu; James Reuben; Massimo Cristofanilli; Zhuang Zuo
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

Review 2.  Inflammatory breast cancer clusters: A hypothesis.

Authors:  Paul H Levine; Salman Hashmi; Ashley A Minaei; Carmela Veneroso
Journal:  World J Clin Oncol       Date:  2014-08-10

3.  How do I treat inflammatory breast cancer?

Authors:  Della Makower; Joseph A Sparano
Journal:  Curr Treat Options Oncol       Date:  2013-03

Review 4.  Inflammatory Breast Cancer: a Separate Entity.

Authors:  Jennifer M Rosenbluth; Beth A Overmoyer
Journal:  Curr Oncol Rep       Date:  2019-08-15       Impact factor: 5.075

5.  Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa.

Authors:  Catherine Schairer; Ahmed Hablas; Ibrahim AbdelBar Seif Eldein; Rabab Gaafar; Henda Rais; Amel Mezlini; Farhat Ben Ayed; Wided Ben Ayoub; Abdellatif Benider; Ali Tahri; Mouna Khouchani; Dalia Aboulazm; Mehdi Karkouri; Saad Eissa; Ruth M Pfeiffer; Shahinaz M Gadalla; Sandra M Swain; Sofia D Merajver; Linda Morris Brown; Amr S Soliman
Journal:  Breast Cancer Res Treat       Date:  2019-04-22       Impact factor: 4.872

6.  RhoC GTPase Is a Potent Regulator of Glutamine Metabolism and N-Acetylaspartate Production in Inflammatory Breast Cancer Cells.

Authors:  Michelle L Wynn; Joel A Yates; Charles R Evans; Lauren D Van Wassenhove; Zhi Fen Wu; Sydney Bridges; Liwei Bao; Chelsea Fournier; Sepideh Ashrafzadeh; Matthew J Merrins; Leslie S Satin; Santiago Schnell; Charles F Burant; Sofia D Merajver
Journal:  J Biol Chem       Date:  2016-04-25       Impact factor: 5.157

7.  Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.

Authors:  Komal Jhaveri; Eleonora Teplinsky; Deborah Silvera; Amanda Valeta-Magara; Rezina Arju; Shah Giashuddin; Yasmeen Sarfraz; Melissa Alexander; Farbod Darvishian; Paul H Levine; Salman Hashmi; Ladan Zolfaghari; Heather J Hoffman; Baljit Singh; Judith D Goldberg; Tsivia Hochman; Silvia Formenti; Francisco J Esteva; Meena S Moran; Robert J Schneider
Journal:  Clin Breast Cancer       Date:  2015-12-01       Impact factor: 3.225

8.  The paradox of E-cadherin: role in response to hypoxia in the tumor microenvironment and regulation of energy metabolism.

Authors:  Khoi Chu; Kimberley M Boley; Ricardo Moraes; Sanford H Barsky; Fredika M Robertson
Journal:  Oncotarget       Date:  2013-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.